Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity.
- Published in:
- Drugs, 2017, v. 77, n. 13, p. 1413, doi. 10.1007/s40265-017-0786-1
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2017 AND VI 77 AND IP 13
Results: 9
1
2
Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases.
- Published in:
- Drugs, 2017, v. 77, n. 13, p. 1461, doi. 10.1007/s40265-017-0788-z
- By:
- Publication type:
- Article
3
Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.
- Published in:
- Drugs, 2017, v. 77, n. 13, p. 1399, doi. 10.1007/s40265-017-0787-0
- By:
- Publication type:
- Article
4
Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.
- Published in:
- Drugs, 2017, v. 77, n. 13, p. 1389, doi. 10.1007/s40265-017-0784-3
- By:
- Publication type:
- Article
5
Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.
- Published in:
- Drugs, 2017, v. 77, n. 13, p. 1423, doi. 10.1007/s40265-017-0789-y
- By:
- Publication type:
- Article
6
Delafloxacin: First Global Approval.
- Published in:
- Drugs, 2017, v. 77, n. 13, p. 1481, doi. 10.1007/s40265-017-0790-5
- By:
- Publication type:
- Article
7
Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
- Published in:
- Drugs, 2017, v. 77, n. 13, p. 1473, doi. 10.1007/s40265-017-0795-0
- By:
- Publication type:
- Article
8
Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
- Published in:
- Drugs, 2017, v. 77, n. 13, p. 1377, doi. 10.1007/s40265-017-0781-6
- By:
- Publication type:
- Article
9
Guselkumab: First Global Approval.
- Published in:
- Drugs, 2017, v. 77, n. 13, p. 1487, doi. 10.1007/s40265-017-0800-7
- By:
- Publication type:
- Article